Classification of pharmaceutical products reimbursed by national health insurance by the ATC system

Chinese Pharmaceutical Journal

Volumn 54, Issue 4, 2002, Pages 283-290

  Kao Yang, Yea Huei ^a   Kuo, Chuei Wen ^a   Hung, Huey Jong ^a   Jia, Shu Wen ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

ATC code; Drug utilization study; National Health Insurance; Pharmaceutical reimbursement

Indexed keywords

DATABASE SYSTEMS; HEALTH CARE;

ELECTRONIC FILES;

DRUG PRODUCTS;

ANABOLIC AGENT; ANTACID AGENT; ANTIANEMIC AGENT; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; ANTITUSSIVE AGENT; ANTIULCER AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD SUBSTITUTE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DERMATOLOGICAL AGENT; DIURETIC AGENT; LAXATIVE; ORAL CONTRACEPTIVE AGENT; PSYCHOTROPIC AGENT; RESPIRATORY TRACT AGENT; SPASMOLYTIC AGENT; UNINDEXED DRUG; VACCINE; VASODILATOR AGENT; VITAMIN;

ARTICLE; CODING; COST CONTROL; DATA BASE; DRUG CLASSIFICATION; DRUG MONITORING; DRUG UTILIZATION; INFORMATION PROCESSING; NATIONAL HEALTH INSURANCE; REIMBURSEMENT; TAIWAN; WORLD HEALTH ORGANIZATION;

EID: 0036703999     PISSN: 10161015     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. th; Taipei, Taiwan. p. 3-1-15.
2. Bureau of National Health Insurance: Business and Finance Briefing 2002. http://www.nhi.gov.tw.
3. Henriksson, F.; Hjortsberg, C.; Rehnberg, C. Pharmaceutical expenditure in Sweden. Health Policy 1999, 47, 125-144.
4. Kane, N. M. Pharmaceutical cost containment and innovation in the United States. Health Policy 1997, 41, suppl S71-89.
5. rd Ed. WHO Collaborating Center for Drug Statistics Methodology: Oslo, 2000.
6. rd Ed.; Strom, B. L. Ed.; John Wiley & Sons, Ltd: West Sussex, 2000; pp 463-481.
7. nd Ed.; The Pharmaceutical Press: London, 1999.
8. th Ed.: Merck Research Laboratories Division of Merck & Co., Inc.: Whitehouse Station, 1996.
9. Annemans, L.; Crott, R.; Clercq, H. C.; Huybrechts, M.; Peys, F.; Robays, H.; Steens, I.; Vanschoubroek, K.; Winderickx, P. Pricing and reimbursement of pharmaceuticals in Belgium. Pharmacoeconomics 1997, 3, 203-209.
10. Pelc, A.; Castab, J. New developments in pricing and drug reimbursement in France. Pharmacoeconomics 1994, 6, suppl 28-35.
11. Burstall, M. L. The management of the cost and utilization of pharmaceuticals in the United Kingdom. Health Policy 1997, 41, suppl S27-43.
12. American Society of Health-care System Pharmacists. American Hospital Formulary System - Drug Information 2000. American Society of Health-care System Pharmacists: Bethesda, 2000.
13. Yang Kao Y. H.; Yang H. C. Drug utilization review of essential amino acid injection. J. Clin. Pharm. Assoc. 1994, 3, 91-98.
14. Yang Kao Y. H.; Kao, S. M.; Chan, K. W. A. A retrospective drug utilization evaluation of antihyperlipidaemic agents in a medical centre in Taiwan. J. Clin. Pharm. Ther. 1997, 22, 291-299.
15. Yang Kao Y. H.; Chen, L. C.; Chan, K. W. A.; Lai, M. L. Changes in ticlopidine utilization pattern after educational intervention. The Chin. Pharm. J. 1999, 51, 347-358.
16. Yang Kao Y. H.; Hsiao, S. H.; Lin, P. W.; Wu, T. J. Surveillance of adverse drug reactions from intravenous fat emulsions in a surgical ward. The Chin. Pharm. J. 1999, 51, 365-373.